Combined prime-boost vaccination against tick-borne encephalitis (TBE) using a recombinant vaccinia virus and a bacterial plasmid both expressing TBE virus non-structural NS1 protein

BMC Microbiology

Volumn 5, Issue , 2005, Pages

  Aleshin, S E ^a   Timofeev, A V ^a,e   Khoretonenko, M V ^a   Zakharova, L G ^b   Pashvykina, G V ^b   Stephenson, J R ^c   Shneider, A M ^d   Altstein, A D ^b  

^a CHUMAKOV INSTITUTE OF POLIOMYELITIS AND VIRAL ENCEPHALITIDES   (Russian Federation)

^b INSTITUTE OF GENE BIOLOGY   (Russian Federation)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d Cure Lab Inc   (United States)

^e ENGELHARDT INSTITUTE OF MOLECULAR BIOLOGY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN NS1; TICK BORNE ENCEPHALITIS VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EMBRYO; GENE EXPRESSION; GENE VECTOR; MALE; MOUSE; NONHUMAN; PATHOGENICITY; PLASMID; PROMOTER REGION; PROTEIN EXPRESSION; PROVOCATION TEST; TICK BORNE ENCEPHALITIS; TICK BORNE ENCEPHALITIS FLAVIVIRUS; VACCINATION; VACCINIA VIRUS; VIRUS RECOMBINANT; VIRUS STRAIN;

ANIMALS; BACTERIA; CYTOMEGALOVIRUS; ENCEPHALITIS VIRUSES, TICK-BORNE; ENCEPHALITIS, TICK-BORNE; HUMANS; IMMUNIZATION, SECONDARY; LETHAL DOSE 50; MICE; MICE, INBRED BALB C; PLASMIDS; VACCINES, DNA; VACCINIA VIRUS; VIRAL NONSTRUCTURAL PROTEINS; VIRAL VACCINES;

ACARI; ANIMALIA; FLAVIVIRUS; TICK-BORNE ENCEPHALITIS VIRUS; VACCINIA VIRUS;

EID: 23944497131     PISSN: 14712180     EISSN: 14712180     Source Type: Journal    
DOI: 10.1186/1471-2180-5-45     Document Type: Article

References (23)

1. Woodland DL: Jump-starting the immune system: prime-boosting comes of age. Trends Immunol 2004, 25:98-104.
2. McShane H, Brookes R, Gilbert S, Hill A: Enhanced immunogenicity of CD4 (+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis. Infect Immun 2001, 69:681-686.
3. Koopman G, Mortier D, Hofman S, Niphuis H, Fagrouch Z, Norley S, Sutter G, Liljestrom P, Heeney JL: Vaccine protection from CD4+ T-cell loss caused by simian immunodeficiency virus (SIV) mac251 is afforded by sequential immunization with three unrelated vaccine vectors encoding multiple SIV antigens. J Gen Virol 2004, 85:2915-2924.
4. Matsui M, Moriya O, Akatsuka T: Enhanced induction of hepatitis C virus-specific cytotoxic T lymphocytes and protective efficacy in mice by DNA vaccination followed by adenovirus boosting in combination with the interleukin-12 expression plasmid. Vaccine 2003, 21:1629-1639.
5. Estcourt MJ, Ramsay AJ, Brooks A, Thomson SA, Medveckzy CJ, Ramshaw IA: Prime-boost immunization generates a high frequency, high-avidity CD8 (+) cytotoxic T lymphocyte population. Int Immunol 2002, 14:31-37.
6. Vuola JM, Keating S, Webster DP, Berthoud T, Dunachie S, Gilbert SC, Hill AV: Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers. J Immunol 2005, 174:449-455.
7. Garzon MR, Berraondo P, Crettaz J, Ochoa L, Vera M, Lasarte JJ, Vales A, Van Rooijen N, Ruiz J, Prieto J, et al.: Induction of gp120-specific protective immune responses by genetic vaccination with linear polyethylenimine-plasmid complex. Vaccine 2005, 23:1384-1392.
8. Meseda CA, Elkins KL, Merchlinsky MJ, Weir JP: Prime-Boost Immunization with DNA and Modified Vaccinia Virus Ankara Vectors Expressing Herpes Simplex Virus-2 Glycoprotein D Elicits Greater Specific Antibody and Cytokine Responses than DNA Vaccine Alone. The Journal of Infectious Diseases 2002, 186:1065-1073.
9. Timofeev AV, Kondrat'eva I, Karganova GG, Stephenson J: [Protective activity of a bacterial plasmid, bearing the gene for the tick-borne encephalitis virus NS1 nonstructural protein]. Vopr Virusol 2001, 46:22-24.
10. Khoretonenko MV, Vorovitch MF, Zakharova LG, Pashvykina GV, Ovsyannikova NV, Stephenson JR, Timofeev AV, Altstein AD, Shneider AM: Vaccinia virus recombinant expressing gene of tickborne encephalitis virus non-structural NS1 protein elicits protective activity in mice. Immunol Lett 2003, 90:161-163.
11. Timofeev AV, Karganova GG: Tick-borne encephalitis vaccine: from past to future Moscow: Pronto Prints Ltd; 2003.
12. Phillpotts RJ, Stephenson JR, Porterfield JS: Antibody-dependent enhancement of tick-borne encephalitis virus infection. J Gen Virol 1985, 66:1831-1837.
13. Jacobs SC, Stephenson JR, Wilkinson GW: High-level expression of the tick-borne encephalitis virus NS1 protein by using an adenovirus-based vector: protection elicited in a murine model. J Virol 1992, 66:2086-2095.
14. Rokitsky PF: Biological statistics. In Vysshaya shkola Minsk, USSR; 1964. (in Russian)
15. Schlesinger JJ, Drandriss MW, Walsh EE: Protection against yellow fever 17D encephalitis in mice by passive transfer of monoclonal antibodies to the non-structural glycoprotein gp48 and by active immunization with gp48. J Immunol 1985, 135:2805-2809.
16. Timofeev AV, Ozherelkov SV, Pronin AV, Deeva AV, Karganova GG, Elbert LB, Stephenson JR: Immunological basis for protection in a murine modelof tick-borne encephalitis by a recombinant adenovirus carrying the gene encoding the NS1 non-structural protein. J Gen Virol 1998, 79:689-695.
17. Mackett M, Smith GL, Moss B: Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci U S A 1982, 79:7415-7419.
18. Altstein AD, Andzhaparidze OG, Antonova TP, Baev AA, Baisar D, Bendukidze KA, et al.: Double recombinants of the vaccinia virus expressing hepatitis B virus surface antigen and herpes simplex virus thymidine kinase. Dokl Akad Nauk SSSR 1986, 289:1493-1496. (in Russian)
19. Chernos VI, Cheliapov NV, Antonova TP, Rakhilina LE, Unanov SS, Al'tshtein AD, Zakharova LG, Fodor II, Bendukidze KA, Komarov FI, et al.: Verification of the safety, inoculability, reactogenicity and antigenic properties of a live recombinant smallpox-hepatitis B vaccine in an experiment in volunteers. Vopr Virusol 1990, 35:132-1355. (in Russian)
20. Altstein AD, Chernos VI: Poxvirus recombinants as potential vaccines. In Concepts in Virology Volume Chapter 35. Edited by: Mahy BWJ, Lvov DK. Switzerland, Harwood Academic Publisher; 1993:381-388.
21. Buller RM, Smith GL, Cremer K, Notkins AL, Moss B: Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature 1985, 317:813-815.
22. Altstein AD, Zakharova LG, Loparev VN, Pashvykina GV, Gorodetsky SI, Chernos VI, Senkevich TG, Antonova TP, Andzhaparidze OG: Development of vaccinia virus recombinant on the basis LIVP strain inducing hepatitis B virus surface antigen. Dokl Akad Nauk SSSR 1985, 285:696-699. (in Russian)
23. Stephenson JR, Crooks AJ, Lee JM: The synthesis of immunogenic polypeptides encoded by tick-borne encephalitis virus. J Gen Virol 1987, 68:1307-1316.